Clinical Trial

Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma

Name: Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma — clinical trial record (NCT06567600)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

In this phase 2 study, researchers aimed to evaluate the efficacy and safety of low-dose gemcitabine and cisplatin chemotherapy and the immune checkpoint inhibitor PD-1/PD-L1 antibody in patients with advanced and unresectable intrahepatic cholangiocarcinoma.

Trial Details

NCT Number	NCT06567600
Lead Sponsor	Third Affiliated Hospital, Sun Yat-Sen University Collaborators: Second Affiliated Hospital of Guangzhou Medical University
Conditions	Intrahepatic Cholangiocarcinoma, Chemotherapy Effect, Immunotherapy
Enrollment	43 participants
Start Date	2024-09-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-08-22